171 related articles for article (PubMed ID: 38155060)
41. Screening logs from a pilot randomized controlled trial of radical cystectomy versus chemoradiation therapy for muscle-invasive bladder cancer.
Kaushik D; Shi Z; Liss MA; Wang H; Jha RP; Choi BY; Pruthi DK; Ha CS; Mansour AM; Svatek RS
Urol Oncol; 2020 Jan; 38(1):4.e1-4.e6. PubMed ID: 31676280
[TBL] [Abstract][Full Text] [Related]
42. RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03).
Wen F; Lin T; Zhang P; Shen Y
Front Oncol; 2023; 13():1233196. PubMed ID: 38269021
[TBL] [Abstract][Full Text] [Related]
43. The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis.
Bruins HM; Aben KK; Arends TJ; van der Heijden AG; Witjes AJ
Urol Oncol; 2016 Apr; 34(4):166.e1-6. PubMed ID: 26705102
[TBL] [Abstract][Full Text] [Related]
44. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
Necchi A; Anichini A; Raggi D; Briganti A; Massa S; Lucianò R; Colecchia M; Giannatempo P; Mortarini R; Bianchi M; Farè E; Monopoli F; Colombo R; Gallina A; Salonia A; Messina A; Ali SM; Madison R; Ross JS; Chung JH; Salvioni R; Mariani L; Montorsi F
J Clin Oncol; 2018 Dec; 36(34):3353-3360. PubMed ID: 30343614
[TBL] [Abstract][Full Text] [Related]
45. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.
Iyer G; Balar AV; Milowsky MI; Bochner BH; Dalbagni G; Donat SM; Herr HW; Huang WC; Taneja SS; Woods M; Ostrovnaya I; Al-Ahmadie H; Arcila ME; Riches JC; Meier A; Bourque C; Shady M; Won H; Rose TL; Kim WY; Kania BE; Boyd ME; Cipolla CK; Regazzi AM; Delbeau D; McCoy AS; Vargas HA; Berger MF; Solit DB; Rosenberg JE; Bajorin DF
J Clin Oncol; 2018 Jul; 36(19):1949-1956. PubMed ID: 29742009
[TBL] [Abstract][Full Text] [Related]
46. ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer.
Sonpavde G; Necchi A; Gupta S; Steinberg GD; Gschwend JE; Van Der Heijden MS; Garzon N; Ibrahim M; Raybold B; Liaw D; Rutstein M; Galsky MD
Future Oncol; 2020 Jan; 16(2):4359-4368. PubMed ID: 31823654
[TBL] [Abstract][Full Text] [Related]
47. Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT).
Schmid SC; Koll FJ; Rödel C; Maisch P; Sauter A; Beckert F; Seitz A; Kübler H; Flentje M; Chun F; Combs SE; Schiller K; Gschwend JE; Retz M
BMC Cancer; 2020 Jan; 20(1):8. PubMed ID: 31900121
[TBL] [Abstract][Full Text] [Related]
48. Neoadjuvant Chemotherapy with Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Muscle-invasive Bladder Cancer: A Retrospective Age-stratified Analysis on Safety and Efficacy.
Hemenway G; Lewis B; Ghatalia P; Anari F; Plimack ER; Kokate R; Handorf E; Deng M; Geynisman DM; Zibelman M
Eur Urol Oncol; 2023 Aug; 6(4):431-436. PubMed ID: 35792045
[TBL] [Abstract][Full Text] [Related]
49. Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor: a retrospective analysis of 143 patients.
Rehme C; Fritsch B; Thomas L; Istin S; Burchert C; Hummel B; Baleanu-Curaj B; Reis H; Szarvas T; Ruebben H; Hadaschik B; Niedworok C
Int Urol Nephrol; 2022 Jan; 54(1):71-79. PubMed ID: 34817753
[TBL] [Abstract][Full Text] [Related]
50. Comparing Pathologic and Survival Outcomes Between Primary and Secondary Muscle Invasive Bladder Cancer When Treated by Radical Cystectomy With or Without Neoadjuvant Chemotherapy.
Benidir T; Lone Z; Zhang A; Nowacki AS; Munoz-Lopez C; Hegde P; Fung K; Fajnzylber J; Abouassaly R; Berglund R; Klein EA; Eltemamy M; Kaouk J; Weight CJ; Almassi N; Pascal-Haber G; Lee BH
Urology; 2022 Oct; 168():137-142. PubMed ID: 35772481
[TBL] [Abstract][Full Text] [Related]
51. Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study.
Koie T; Ohyama C; Hashimoto Y; Hatakeyama S; Yamamoto H; Yoneyama T; Kamimura N
Int J Clin Oncol; 2013 Aug; 18(4):724-30. PubMed ID: 23011100
[TBL] [Abstract][Full Text] [Related]
52. Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
Martinez Chanza N; Soukane L; Barthelemy P; Carnot A; Gil T; Casert V; Vanhaudenarde V; Sautois B; Staudacher L; Van den Brande J; Culine S; Seront E; Gizzi M; Albisinni S; Tricard T; Fantoni JC; Paesmans M; Caparica R; Roumeguere T; Awada A
BMC Cancer; 2021 Dec; 21(1):1292. PubMed ID: 34856936
[TBL] [Abstract][Full Text] [Related]
53. Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?
Ghandour RA; Kusin S; Wong D; Meng X; Singla N; Freifeld Y; Bagrodia A; Margulis V; Sagalowsky A; Lotan Y; Woldu SL
Urol Oncol; 2020 Sep; 38(9):736.e11-736.e18. PubMed ID: 32684514
[TBL] [Abstract][Full Text] [Related]
54. Role of immunotherapy in localized muscle invasive urothelial cancer.
Kaur J; Choi W; Geynisman DM; Plimack ER; Ghatalia P
Ther Adv Med Oncol; 2021; 13():17588359211045858. PubMed ID: 34567274
[TBL] [Abstract][Full Text] [Related]
55. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?
Brant A; Kates M; Chappidi MR; Patel HD; Sopko NA; Netto GJ; Baras AS; Hahn NM; Pierorazio PM; Bivalacqua TJ
Urol Oncol; 2017 Jan; 35(1):34.e17-34.e25. PubMed ID: 27639777
[TBL] [Abstract][Full Text] [Related]
56. Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
Meleis L; Moore R; Inman BA; Harrison MR
J Oncol Pharm Pract; 2020 Mar; 26(2):330-337. PubMed ID: 31081469
[TBL] [Abstract][Full Text] [Related]
57. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients.
Hautmann RE; de Petriconi RC; Pfeiffer C; Volkmer BG
Eur Urol; 2012 May; 61(5):1039-47. PubMed ID: 22381169
[TBL] [Abstract][Full Text] [Related]
58. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience.
Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
BJU Int; 2019 Jun; 123(6):1011-1019. PubMed ID: 30623554
[TBL] [Abstract][Full Text] [Related]
59. Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer.
Reignier PL; Gauthier H; Hennequin C; Aussedat Q; Xylinas E; Desgrandchamps F; Culine S; Masson-Lecomte A; Dumont C
World J Urol; 2023 Nov; 41(11):3249-3255. PubMed ID: 37410102
[TBL] [Abstract][Full Text] [Related]
60. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.
Metcalfe MJ; Ferguson JE; Li R; Xiao L; Guo CC; Czerniak BA; Siefker-Radtke A; Pretzsch SM; Navai N; McConkey DJ; Kamat AM; Campbell M; Dinney C
Eur Urol Focus; 2017 Dec; 3(6):577-583. PubMed ID: 28753816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
